US equities
|
TSLA
$394.46
▲+5.97%
MU
$907.09
▲+3.37%
SPCX
$148.83
▲+0.91%
NVDA
$215.68
▲+2.24%
META
$641.54
▼-0.17%
SNDK
$1,263.05
▲+2.02%
AAPL
$344.40
▼-0.95%
INTC
$90.91
▲+4.54%
TSLA
$394.46
▲+5.97%
MU
$907.09
▲+3.37%
SPCX
$148.83
▲+0.91%
NVDA
$215.68
▲+2.24%
META
$641.54
▼-0.17%
SNDK
$1,263.05
▲+2.02%
AAPL
$344.40
▼-0.95%
INTC
$90.91
▲+4.54%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Elite Pharms Inc
(OP:
ELTP
)
0.2412
-0.0086 (-3.44%)
Delayed Quote
Updated: 12:06 PM EDT, Oct 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Elite Pharms Inc
< Previous
1
2
Next >
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
June 16, 2025
Northvale, New Jersey--(Newsfile Corp. - June 16, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company...
Via
Newsfile
Topics
Intellectual Property
Elite Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets
April 30, 2025
Northvale, New Jersey--(Newsfile Corp. - April 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical...
Via
Newsfile
Elite Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line
March 03, 2025
Northvale, New Jersey--(Newsfile Corp. - March 3, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...
Via
Newsfile
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2025 ended December 31, 2024 and Provides Conference Call Information
February 13, 2025
Northvale, New Jersey--(Newsfile Corp. - February 13, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...
Via
Newsfile
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
February 14, 2024
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information
November 14, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2025 Financial Results on February 14, 2025
February 10, 2025
Northvale, New Jersey--(Newsfile Corp. - February 10, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...
Via
Newsfile
Elite Pharmaceuticals Announces Commercial Launch of Generic Vyvanse(R)
December 26, 2024
Northvale, New Jersey--(Newsfile Corp. - December 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...
Via
Newsfile
Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets
December 02, 2024
Northvale, New Jersey--(Newsfile Corp. - December 2, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...
Via
Newsfile
Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse
November 18, 2024
Northvale, New Jersey--(Newsfile Corp. - November 18, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...
Via
Newsfile
Elite Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024 ended June 30, 2023 and Provides Conference Call Information
August 14, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2024 Financial Results on August 15, 2023
August 09, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 and Provides Conference Call Information
November 14, 2024
Northvale, New Jersey--(Newsfile Corp. - November 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...
Via
Newsfile
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024
November 07, 2024
Northvale, New Jersey--(Newsfile Corp. - November 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...
Via
Newsfile
Elite Pharmaceuticals' Generic Adderall(R) Receives Marketing Approval from the Israeli Ministry of Health
October 10, 2024
Northvale, New Jersey--(Newsfile Corp. - October 10, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...
Via
Newsfile
Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Codeine Phosphate Tablets
October 07, 2024
Northvale, New Jersey--(Newsfile Corp. - October 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company...
Via
Newsfile
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2023 and Provides Conference Call Information
June 29, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate Sodium
August 27, 2024
Northvale, New Jersey--(Newsfile Corp. - August 27, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...
Via
Newsfile
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2025 Ended June 30, 2024 and Provides Conference Call Information
August 14, 2024
Northvale, New Jersey--(Newsfile Corp. - August 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...
Via
Newsfile
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2025 Financial Results on August 15, 2024
August 09, 2024
Northvale, New Jersey--(Newsfile Corp. - August 9, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...
Via
Newsfile
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Conference Call Information
July 01, 2024
Northvale, New Jersey--(Newsfile Corp. - July 1, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...
Via
Newsfile
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2024 Financial Results on July 2, 2024
June 26, 2024
Northvale, New Jersey--(Newsfile Corp. - June 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty...
Via
Newsfile
Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate
May 20, 2024
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024
February 08, 2024
Via
ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant
December 26, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC
December 12, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023
November 10, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product
September 25, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer
September 07, 2023
Via
ACCESSWIRE
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
August 28, 2023
Via
ACCESSWIRE
< Previous
1
2
Next >
